Format

Send to

Choose Destination
Br J Haematol. 2017 Jul;178(2):250-256. doi: 10.1111/bjh.14667. Epub 2017 Apr 17.

Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.

Author information

1
Weill Cornell Medicine, New York, NY, USA.
2
Georgetown University Hospital, Washington, DC, USA.
3
Dalhousie University, Halifax, NS, Canada.
4
University of Virginia Health System, Charlottesville, VA, USA.
5
University of Wisconsin Hospital, Madison, WI, USA.
6
University of Rochester, Rochester, NY, USA.
7
Ottawa Hospital, Ottawa, ON, Canada.
8
Dana-Farber Cancer Institute, Boston, MA, USA.
9
Beth Israel Deconess Medical Center, Boston, MA, USA.
10
Stanford University, San Francisco, CA, USA.
11
Washington University School of Medicine, St. Louis, MO, USA.
12
Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada.
13
West Cancer Center, Memphis, TN, USA.
14
Health Sciences North, Sudbury, ON, Canada.
15
Royal Melbourne Hospital, Melbourne, Vic., Australia.
16
Bennet Cancer Center, Stamford, CT, USA.
17
Auxillio Cancer Center, San Juan, Puerto Rico.
18
St. Vincent's Hospital, Sydney, NSW, Australia.
19
St. Luke's Mountain States Tumor Institute, Boise, ID, USA.
20
Royal Victoria Hospital, Barrie, ON, Canada.
21
Cleveland Clinic, Cleveland, OH, USA.

Abstract

Despite the long history of bendamustine as treatment for indolent non-Hodgkin lymphoma, long-term efficacy and toxicity data are minimal. We reviewed long-term data from three clinical trials to characterize the toxicity and efficacy of patients receiving bendamustine. Data were available for 149 subjects at 21 sites. The median age was 60 years at the start of bendamustine (range 39-84), and patients had received a median of 3 prior therapies. The histologies included grades 1-2 follicular lymphoma (FL; n = 73), grade 3 FL (n = 23), small lymphocytic lymphoma (n = 20), marginal zone lymphoma (n = 15), mantle cell lymphoma (n = 9), transformed lymphomas (n = 5), lymphoplasmacytic lymphoma (n = 2) and not reported (n = 2). The median event-free survival was 14·1 months. Nine of 12 attempted stem cell collections were successful. With a median follow-up of 8·9 years, 23 patients developed 25 cancers, including 8 patients with myelodysplastic syndrome/acute myeloid leukaemia. These data provide important information regarding the long-term toxicity of bendamustine in previously treated patients. A small but meaningful number of patients achieved durable remissions following bendamustine. These rigorously collected, patient-level, long-term follow-up data provide reassurance that bendamustine or bendamustine plus rituximab is associated with efficacy and safety for patients with relapsed or refractory indolent non-Hodgkin lymphoma.

KEYWORDS:

chemotherapy; haemotoxicity; lymphomas

PMID:
28419413
PMCID:
PMC5737737
DOI:
10.1111/bjh.14667
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center